BO1:F BioCryst Pharmaceuticals Inc

EUR 4.44 -0.34 -7.148829
Icon

BioCryst Pharmaceuticals Inc (BO1:F) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | F
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 4.44

-0.34 (-7.15)%

EUR 1.00B

2.00K

N/A

N/A

Icon

BO1:F

BioCryst Pharmaceuticals Inc (EUR)
COMMON STOCK | F
EUR 4.44
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 1.00B

N/A

EUR 4.44

BioCryst Pharmaceuticals Inc (BO1:F) Stock Forecast

N/A

Based on the BioCryst Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for BioCryst Pharmaceuticals Inc is not available over the next 12 months. BioCryst Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioCryst Pharmaceuticals Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, BioCryst Pharmaceuticals Inc’s stock price was EUR 4.44. BioCryst Pharmaceuticals Inc’s stock price has changed by +2.90% over the past week, -0.11% over the past month and -39.89% over the last year.

No recent analyst target price found for BioCryst Pharmaceuticals Inc
No recent average analyst rating found for BioCryst Pharmaceuticals Inc

Company Overview BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPI...Read More

https://www.biocryst.com

4505 Emperor Boulevard, Durham, NC, United States, 27703

536

December

EUR

Germany

Adjusted Closing Price for BioCryst Pharmaceuticals Inc (BO1:F)

Loading...

Unadjusted Closing Price for BioCryst Pharmaceuticals Inc (BO1:F)

Loading...

Share Trading Volume for BioCryst Pharmaceuticals Inc Shares

Loading...

Compare Performance of BioCryst Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BO1:F

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To BioCryst Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NOVA:F
Novo Nordisk A/S +1.00 (+0.85%) EUR525.74B 45.80 4.49

ETFs Containing BO1

Symbol Name BO1's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About BioCryst Pharmaceuticals Inc (BO1:F) Stock

Stock Target Advisor's fundamental analysis for BioCryst Pharmaceuticals Inc's stock is Slightly Bearish.

Unfortunately we do not have enough data on BO1:F's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on BO1:F's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on BO1:F's stock to indicate if its overvalued.

The last closing price of BO1:F's stock was EUR 4.44.

The most recent market capitalization for BO1:F is EUR 1.00B.

Unfortunately we do not have enough analyst data on BO1:F's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains BioCryst Pharmaceuticals Inc's stock.

As per our most recent records BioCryst Pharmaceuticals Inc has 536 Employees.

BioCryst Pharmaceuticals Inc's registered address is 4505 Emperor Boulevard, Durham, NC, United States, 27703. You can get more information about it from BioCryst Pharmaceuticals Inc's website at https://www.biocryst.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...